CN116804053A - anti-HBcAg monoclonal antibody and application thereof - Google Patents
anti-HBcAg monoclonal antibody and application thereof Download PDFInfo
- Publication number
- CN116804053A CN116804053A CN202310965283.2A CN202310965283A CN116804053A CN 116804053 A CN116804053 A CN 116804053A CN 202310965283 A CN202310965283 A CN 202310965283A CN 116804053 A CN116804053 A CN 116804053A
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence shown
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 124
- 208000002672 hepatitis B Diseases 0.000 claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 241000700721 Hepatitis B virus Species 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000029812 viral genome replication Effects 0.000 claims description 5
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 101710142246 External core antigen Proteins 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 description 51
- 239000000243 solution Substances 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 101710132601 Capsid protein Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 239000011259 mixed solution Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 6
- 208000006454 hepatitis Diseases 0.000 description 6
- 231100000283 hepatitis Toxicity 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- -1 glidants Substances 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 238000012207 quantitative assay Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000008394 flocculating agent Substances 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 206010059193 Acute hepatitis B Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 208000037628 acute hepatitis B virus infection Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229940050929 polyethylene glycol 3350 Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention relates to an anti-HBcAg monoclonal antibody and application thereof, belonging to the technical field of biology. The present invention provides an anti-HBcAg monoclonal antibody, the heavy chain variable region of which comprises CDR1 shown in SEQ ID NO.1 or SEQ ID NO.19, CDR2 shown in SEQ ID NO.2 or SEQ ID NO.20, and/or CDR3 shown in SEQ ID NO.3 or SEQ ID NO.21, the light chain variable region comprises CDR1 shown in SEQ ID NO.4 or SEQ ID NO.22, CDR2 shown in SEQ ID NO.5 or SEQ ID NO.23, and/or CDR3 shown in SEQ ID NO.6 or SEQ ID NO.24, which is capable of significantly inhibiting expression of HBsAg, HBeAg and HBV DNA.
Description
Technical Field
The invention relates to an anti-HBcAg monoclonal antibody and application thereof, belonging to the technical field of biology.
Background
The hepatitis B virus (Hepatitis B virus, HBV) is a hepadnavirus, consists of an envelope and a nucleocapsid, has strong infectivity, mainly invades human liver, and can cause related diseases such as acute viral hepatitis B (Acute Hepatitis B, AHB), chronic viral hepatitis B (Chronic Hepatitis B, CHB), liver fibrosis, liver cancer and the like after infection.
At present, nucleoside (nucleotide) antiviral drugs are generally used for inhibiting the replication of hepatitis B virus, so as to treat hepatitis B virus infection and related diseases caused by the hepatitis B virus infection. However, nucleoside (nucleotide) antiviral drugs generally have the problems of low clinical cure rate and easy virus rebound and even liver failure after drug withdrawal. Interferon may also be used for antiviral treatment of hepatitis b virus infection. However, most patients have poor tolerance to interferon, there are many adverse reactions, and only 3% to 7% of chronic viral hepatitis b patients treated for 1 year get hepatitis b surface antigen (Hepatitis B surface antigen, HBsAg) clearance (hepatitis b surface antigen clearance is a sign of clinical cure or functional cure of chronic viral hepatitis b).
Monoclonal antibodies (Monoclonal antibody) are highly homogeneous antibodies raised against only one specific epitope by a single B cell clone. Compared with interferon and nucleotide antiviral drugs, the monoclonal antibody drug has the advantages of strong specificity, high sensitivity, high effectiveness and good safety in treatment. The monoclonal antibody medicine capable of effectively inhibiting the replication of the hepatitis B virus is expected to overcome the defects of the existing anti-hepatitis B virus infection medicine.
The genome of hepatitis b virus consists of an incomplete circular double-stranded DNA, comprising four open reading frames (open reading frame, ORF) encoding proteins required for viral replication and packaging, the S, C, P and X regions. Several proteins encoded by the open reading frame elicit specific immune responses against hepatitis b virus, such as the hepatitis b surface antigen (Hepatitis B surface antigen, HBsAg) mentioned above, as well as hepatitis b e antigen (Hepatitis B e antigen, HBeAg) and hepatitis b core antigen (Hepatitis B core antigen, HBcAg).
Among them, HBcAg has strong immunogenicity, and almost all hepatitis b virus infected persons can detect a hepatitis b core antibody (anti-HBc) generated by HBcAg eliciting an immune reaction, but it is widely thought that anti-HBc is not a protective antibody, has only a certain epidemiological investigation significance, and because anti-HBc can exist in serum for a long time, is a sign of acute infection and later chronic infection of hepatitis b virus, anti-HBc has been widely used in clinical screening and diagnosis of chronic viral hepatitis b (CHB). At present, no anti-HBcAg monoclonal antibody capable of effectively inhibiting replication of hepatitis B virus exists.
Disclosure of Invention
In order to solve the above problems, the present invention provides an anti-HBcAg monoclonal antibody, wherein the heavy chain variable region of the monoclonal antibody comprises CDR1 with an amino acid sequence shown as SEQ ID NO.1 or SEQ ID NO.19, CDR2 with an amino acid sequence shown as SEQ ID NO.2 or SEQ ID NO.20, and/or CDR3 with an amino acid sequence shown as SEQ ID NO.3 or SEQ ID NO.21, and the light chain variable region comprises CDR1 with an amino acid sequence shown as SEQ ID NO.4 or SEQ ID NO.22, CDR2 with an amino acid sequence shown as SEQ ID NO.5 or SEQ ID NO.23, and/or CDR3 with an amino acid sequence shown as SEQ ID NO.6 or SEQ ID NO. 24.
In one embodiment of the present invention, the heavy chain variable region of the monoclonal antibody comprises a CDR1 with an amino acid sequence shown as SEQ ID No.1, a CDR2 with an amino acid sequence shown as SEQ ID No.2, and/or a CDR3 with an amino acid sequence shown as SEQ ID No.3, and the light chain variable region comprises a CDR1 with an amino acid sequence shown as SEQ ID No.4, a CDR2 with an amino acid sequence shown as SEQ ID No.5, and/or a CDR3 with an amino acid sequence shown as SEQ ID No. 6;
alternatively, the heavy chain variable region of the monoclonal antibody comprises a CDR1 with an amino acid sequence shown as SEQ ID NO.19, a CDR2 with an amino acid sequence shown as SEQ ID NO.20 and/or a CDR3 with an amino acid sequence shown as SEQ ID NO.21, and the light chain variable region comprises a CDR1 with an amino acid sequence shown as SEQ ID NO.22, a CDR2 with an amino acid sequence shown as SEQ ID NO.23 and/or a CDR3 with an amino acid sequence shown as SEQ ID NO. 24.
In one embodiment of the present invention, the heavy chain variable region of the monoclonal antibody comprises a CDR1 with an amino acid sequence shown as SEQ ID No.1, a CDR2 with an amino acid sequence shown as SEQ ID No.2, and a CDR3 with an amino acid sequence shown as SEQ ID No.3, and the light chain variable region comprises a CDR1 with an amino acid sequence shown as SEQ ID No.4, a CDR2 with an amino acid sequence shown as SEQ ID No.5, and a CDR3 with an amino acid sequence shown as SEQ ID No. 6;
alternatively, the heavy chain variable region of the monoclonal antibody comprises a CDR1 with an amino acid sequence shown as SEQ ID NO.19, a CDR2 with an amino acid sequence shown as SEQ ID NO.20 and a CDR3 with an amino acid sequence shown as SEQ ID NO.21, and the light chain variable region comprises a CDR1 with an amino acid sequence shown as SEQ ID NO.22, a CDR2 with an amino acid sequence shown as SEQ ID NO.23 and a CDR3 with an amino acid sequence shown as SEQ ID NO. 24.
In one embodiment of the invention, the heavy chain variable region of the monoclonal antibody comprises FR1 of the amino acid sequence shown as SEQ ID NO.7 or SEQ ID NO.25, FR2 of the amino acid sequence shown as SEQ ID NO.8 or SEQ ID NO.26, FR3 of the amino acid sequence shown as SEQ ID NO.9 or SEQ ID NO.27, and/or FR4 of the amino acid sequence shown as SEQ ID NO.10 or SEQ ID NO.28, the light chain variable region comprises FR1 of the amino acid sequence shown as SEQ ID NO.11 or SEQ ID NO.29, FR2 of the amino acid sequence shown as SEQ ID NO.12 or SEQ ID NO.30, FR3 of the amino acid sequence shown as SEQ ID NO.13 or SEQ ID NO.31, and/or FR4 of the amino acid sequence shown as SEQ ID NO.14 or SEQ ID NO. 32.
In one embodiment of the invention, the heavy chain variable region of the monoclonal antibody comprises FR1 with an amino acid sequence shown as SEQ ID NO.7, FR2 with an amino acid sequence shown as SEQ ID NO.8, FR3 with an amino acid sequence shown as SEQ ID NO.9 and/or FR4 with an amino acid sequence shown as SEQ ID NO.10, and the light chain variable region comprises FR1 with an amino acid sequence shown as SEQ ID NO.11, FR2 with an amino acid sequence shown as SEQ ID NO.12, FR3 with an amino acid sequence shown as SEQ ID NO.13 and/or FR4 with an amino acid sequence shown as SEQ ID NO. 14;
alternatively, the heavy chain variable region of the monoclonal antibody comprises FR1 with an amino acid sequence shown as SEQ ID NO.25, FR2 with an amino acid sequence shown as SEQ ID NO.26, FR3 with an amino acid sequence shown as SEQ ID NO.27 and/or FR4 with an amino acid sequence shown as SEQ ID NO.28, and the light chain variable region comprises FR1 with an amino acid sequence shown as SEQ ID NO.29, FR2 with an amino acid sequence shown as SEQ ID NO.30, FR3 with an amino acid sequence shown as SEQ ID NO.31 and/or FR4 with an amino acid sequence shown as SEQ ID NO. 32.
In one embodiment of the invention, the heavy chain variable region of the monoclonal antibody comprises FR1 with an amino acid sequence shown as SEQ ID NO.7, FR2 with an amino acid sequence shown as SEQ ID NO.8, FR3 with an amino acid sequence shown as SEQ ID NO.9 and FR4 with an amino acid sequence shown as SEQ ID NO.10, and the light chain variable region comprises FR1 with an amino acid sequence shown as SEQ ID NO.11, FR2 with an amino acid sequence shown as SEQ ID NO.12, FR3 with an amino acid sequence shown as SEQ ID NO.13 and FR4 with an amino acid sequence shown as SEQ ID NO. 14;
alternatively, the heavy chain variable region of the monoclonal antibody comprises FR1 with an amino acid sequence shown as SEQ ID NO.25, FR2 with an amino acid sequence shown as SEQ ID NO.26, FR3 with an amino acid sequence shown as SEQ ID NO.27 and FR4 with an amino acid sequence shown as SEQ ID NO.28, and the light chain variable region comprises FR1 with an amino acid sequence shown as SEQ ID NO.29, FR2 with an amino acid sequence shown as SEQ ID NO.30, FR3 with an amino acid sequence shown as SEQ ID NO.31 and FR4 with an amino acid sequence shown as SEQ ID NO. 32.
In one embodiment of the invention, the amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO.15, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 16;
alternatively, the amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO.33, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 34.
In one embodiment of the invention, the nucleotide sequence of the gene encoding the heavy chain variable region is shown in SEQ ID NO.17 and the nucleotide sequence of the gene encoding the light chain variable region is shown in SEQ ID NO. 18;
alternatively, the nucleotide sequence of the gene encoding the heavy chain variable region is shown as SEQ ID NO.35, and the nucleotide sequence of the gene encoding the light chain variable region is shown as SEQ ID NO. 36.
In one embodiment of the invention, the light chain and the heavy chain are linked by disulfide bonds.
The invention also provides a gene which codes for the monoclonal antibody.
The invention also provides a recombinant plasmid carrying the gene.
In one embodiment of the invention, the recombinant plasmid vector is a pET-30a (+) expression vector, a pcDNA3.1/GS expression vector, a pXMJ19 expression vector, a pBAD24 expression vector or a pMAL-c2x expression vector.
The invention also provides a host cell transfected with the recombinant plasmid; alternatively, the genome of the host cell integrates the above-described genes.
In one embodiment of the invention, the host cell is a HepG2 cell or a HepG2.2.15 cell.
The invention also provides a method for preparing the monoclonal antibody, which comprises the following steps: inoculating the host cells into a cell culture medium for culture to obtain a culture solution; the monoclonal antibody is separated and extracted from the culture solution.
The invention also provides a medicament containing the monoclonal antibody, and the medicament has at least one of the following uses:
(a) Inhibiting hepatitis b virus replication;
(b) Preventing and/or treating hepatitis B virus infection; and/or the number of the groups of groups,
(c) Preventing and/or treating diseases caused by hepatitis B virus infection.
In one embodiment of the present invention, the disease associated with hepatitis b virus infection includes one or more of acute viral hepatitis b, chronic viral hepatitis b, liver fibrosis or liver cancer.
In one embodiment of the invention, the medicament further comprises a pharmaceutical carrier and/or a pharmaceutical excipient.
In one embodiment of the invention, the pharmaceutical carrier comprises one or more of microcapsules, microspheres, nanoparticles or liposomes.
In one embodiment of the present invention, the pharmaceutical excipients comprise one or more of solvents, propellants, solubilizing agents, co-solvents, emulsifiers, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure modifiers, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-binding agents, integration agents, permeation promoters, pH modifiers, buffers, plasticizers, surfactants, foaming agents, antifoaming agents, thickening agents, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculants, filter aids, or release retarders.
In one embodiment of the invention, the medicament is in the form of a powder, tablet, granule, capsule, solution, emulsion, suspension or injection.
The invention also provides the use of the monoclonal antibody or the gene or the recombinant plasmid or the host cell or the method in the preparation of a medicament having at least one of the following uses:
(a) Inhibiting hepatitis b virus replication;
(b) Preventing and/or treating hepatitis B virus infection; and/or the number of the groups of groups,
(c) Preventing and/or treating diseases caused by hepatitis B virus infection.
In one embodiment of the present invention, the disease associated with hepatitis b virus infection includes one or more of acute viral hepatitis b, chronic viral hepatitis b, liver fibrosis or liver cancer.
In one embodiment of the invention, the medicament further comprises a pharmaceutical carrier and/or a pharmaceutical excipient.
In one embodiment of the invention, the pharmaceutical carrier comprises one or more of microcapsules, microspheres, nanoparticles or liposomes.
In one embodiment of the present invention, the pharmaceutical excipients comprise one or more of solvents, propellants, solubilizing agents, co-solvents, emulsifiers, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure modifiers, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-binding agents, integration agents, permeation promoters, pH modifiers, buffers, plasticizers, surfactants, foaming agents, antifoaming agents, thickening agents, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculants, filter aids, or release retarders.
In one embodiment of the invention, the medicament is in the form of a powder, tablet, granule, capsule, solution, emulsion, suspension or injection.
The technical scheme of the invention has the following advantages:
the invention provides an anti-HBcAg monoclonal antibody, wherein the heavy chain variable region of the monoclonal antibody comprises a CDR1 with an amino acid sequence shown as SEQ ID NO.1 or SEQ ID NO.19, a CDR2 with an amino acid sequence shown as SEQ ID NO.2 or SEQ ID NO.20, and/or a CDR3 with an amino acid sequence shown as SEQ ID NO.3 or SEQ ID NO.21, the light chain variable region comprises a CDR1 with an amino acid sequence shown as SEQ ID NO.4 or SEQ ID NO.22, a CDR2 with an amino acid sequence shown as SEQ ID NO.5 or SEQ ID NO.23, and/or a CDR3 with an amino acid sequence shown as SEQ ID NO.6 or SEQ ID NO. 24. In vitro experiments show that the monoclonal antibody can remarkably inhibit the expression of HBsAg, HBeAg and HBV DNA of HepG2.2.15 cells and HepAD38 cells, has the function of inhibiting the replication of hepatitis B virus, and can be prepared in a large quantity in a short time, so that the monoclonal antibody has great application prospect in preparing medicines for inhibiting the replication of hepatitis B virus, preventing and/or treating hepatitis B virus infection and/or preventing and/or treating related diseases caused by the hepatitis B virus infection.
Detailed Description
The following examples are provided for a better understanding of the present invention and are not limited to the preferred embodiments described herein, but are not intended to limit the scope of the invention, any product which is the same or similar to the present invention, whether in light of the present teachings or in combination with other prior art features, falls within the scope of the present invention.
The following examples do not identify specific experimental procedures or conditions, which may be followed by procedures or conditions of conventional experimental procedures described in the literature in this field. The reagents or apparatus used were conventional reagent products commercially available without the manufacturer's knowledge.
Experimental example 1: preparation, extraction and identification of anti-HBcAg monoclonal antibody
1. HBcAg immunized mice
Balb/c mice (females, 8-10 weeks old, purchased from Guangdong medical laboratory animal center) were immunized with HBcAg protein antigen (Orb 384353, biorbyt) having a purity of greater than 90% and an amino acid sequence shown in SEQ ID NO. 37. The specific immunization procedure is as follows:
performing primary immunization, primary boosting immunization and secondary boosting immunization respectively at 0d, 14d and 21d, taking blood for 24d, separating serum, detecting the specific antibody titer in the serum by ELISA (enzyme-linked immunosorbent assay), and performing tertiary boosting immunization when the titer reaches more than 10000 to obtain HBcAg immunized mice;
in the first immunization, HBcAg protein antigen was diluted to a concentration of 1mg/mL using phosphate buffer (PBS buffer, concentration 0.01M, pH 7.2) to obtain a diluted solution, and then the diluted solution was mixed with Freund's complete adjuvant (F5881, sigma-Aldrich) according to Freund's complete adjuvant: dilution = 1:1, obtaining an immune preparation, and finally injecting the immune preparation into Balb/c mice subcutaneously in a multi-point manner, wherein the immune dosage is 200 mu L/mouse; the first boost and the second boost were identical to the first boost except that the adjuvant was replaced with Freund's incomplete adjuvant F5506, sigma-Aldrich); third boost the remaining steps were consistent with the first boost and the second boost except that subcutaneous multipoint injection was changed to tail vein injection.
2. Mouse spleen cell and myeloma cell fusion
(1) HBcAg immunized mice were anesthetized and then blood was collected from the eyeballs (serum was subsequently collected as a positive control for later screening, or other in vivo and in vitro experiments);
(2) After killing HBcAg immunized mice by neck fracture, putting the mice into 75% (v/v) alcohol for soaking and sterilizing for 5 minutes;
(3) Dissecting and taking out the spleen of the mouse in a sterile super clean bench, putting the spleen into a 70 mu m filter screen arranged on a 50mL centrifuge tube, lightly grinding the spleen into single cells by using a pestle end of a 5mL sterile syringe, adding 30mL serum-free DMEM (purchased from Gibco) for washing 1 time, centrifuging for 8min at 300g, discarding the supernatant, and finally adding 20mL serum-free DMEM to resuspend the spleen cells and counting under a microscope to obtain spleen cell suspension; placing NS-1 cells (mouse myeloma cells purchased from ATCC) into a 50mL centrifuge tube, adding 30mL of serum-free DMEM to wash for 1 time, centrifuging for 8min at 300g, discarding the supernatant, adding 40mL of serum-free DMEM to resuspend the NS-1 cells, and counting under a microscope to obtain an NS-1 cell suspension;
(4) The NS-1 cell suspension was added to the spleen cell suspension to 25X 10 cells in each mouse 6 Mixing NS-1 cells, centrifuging for 8min at 300g, discarding the supernatant to obtain mixed cells, then adding 40mL serum-free DMEM for washing for 1 time, centrifuging for 8min at 300g, and discarding the supernatant to obtain washed mixed cells;
(5) After beating the bottom of a 50mL centrifuge tube to disperse the washed mixed cells, 1mL of 50% (w/v, g/100 mL) polyethylene glycol 3350 (P-3640, sigma) aqueous solution (prepared in advance and filtered for sterilization) is added dropwise in 1min, then a 1mL straw is used for uniformly stirring for 1min, then 4mL of serum-free DMEM is added dropwise in 4min, then 10mL of serum-free DMEM is added dropwise in 2min, and finally water bath is carried out at 37 ℃ for 10min;
(6) 30mL of DMEM containing 10% (v/v) fetal bovine serum (purchased from Gibco) is added into a 50mL centrifuge tube, uniformly mixed, 300g is centrifuged for 8min, the supernatant is discarded, and then 20mL of DMEM containing 20% (v/v) fetal bovine serum is added to resuspend the mixed cells, so as to obtain a mixed cell suspension;
(7) Firstly, respectively adding 10mL of mixed cell suspension into two new 50mL centrifuge tubes, then adding 40mL of DMEM containing 20% (v/v) fetal bovine serum into each centrifuge tube, and uniformly mixing to obtain mixed solution;
(8) Pouring the mixed solution in two 50mL centrifuge tubes into a sterile sample adding tank, adding the mixed solution into a 96-well plate by using a row gun according to the addition amount of 100 mu L/hole for plating, and paving 5 96-well plates for every 50mL cell suspension, wherein 10 96-well plates are paved in total;
(9) After the completion of the plate laying, the mixture was put into 5% (v/v) CO at 37 DEG C 2 Is cultured for 20 hours;
(10) 2 XHAT medium (YZ-H0262-1 VL, solarbio) was added to a 96-well plate at an addition rate of 100. Mu.L/well using a lance, and returned to 37℃at 5% (v/v) CO 2 During the culture, cell culture supernatants having wells grown from the clones were collected by observation at intervals.
3. ELISA screening of anti-HBcAg monoclonal antibodies
(1) Collecting 80 mu L of cell culture supernatant from which cloning holes grow in a 96-well plate, and marking positions;
(2) The quantitative and qualitative kit (purchased from Beijing Wantai) for detecting the core antibody is taken out and rewarmed to room temperature (25 ℃) 30min in advance;
(3) 50 mu L of sample diluent is firstly added into each well of a 96-well plate, and 50 mu L of cell culture supernatant to be detected, 50 mu L of standard substance and 50 mu L of negative sample are respectively added;
(4) Pasting a film on a 96-well plate, and incubating for 30min at room temperature (25 ℃);
(5) Preparing a washing Buffer solution (Wash Buffer,30mL of concentrated solution and 570mL of deionized water), adding 300 mu L of the washing Buffer solution into each well of a 96-well plate, and washing the plate on a plate washer for 5 times;
(6) Removing liquid in the wells, then beating the wells to dry, and adding 100 mu L of enzyme-labeled reagent into each well of the 96-well plate;
(7) Pasting a film on a 96-well plate, and incubating for 30min at room temperature (25 ℃) under the dark condition;
(8) Adding 300 mu L of washing buffer solution into each well of a 96-well plate, and washing the plate on a plate washer for 5 times;
(9) Removing liquid in the wells, then beating to dry, adding 50 mu L of liquid A and 50 mu L of liquid B into each well of the 96-well plate, shaking and mixing uniformly, and developing for 15min at 37 ℃ in dark places;
(10) Adding 50 mu L of stop solution into each well of a 96-well plate, vibrating and uniformly mixing, using an enzyme-labeled analyzer within 10min, and setting a detection absorbance value with a wavelength of 450nm (630 nm is used as a control wavelength);
(11) Cells in positive cloning wells were selected based on OD values of standard wells and negative wells.
4. ELISA positive cloning hole cell cloning
(1) Mixing cells in the positive cloning holes uniformly by using a sample gun, and counting under a microscope to calculate the cell concentration;
(2) Adding cells in 100 positive cloning holes into 10mL 1 XHT culture medium (YZ-H0262-1 VL, solarbio), and mixing to obtain mixed solution;
(3) Pouring the mixed solution into a sterile tank, adding into 96-well plate with a discharge gun at an addition rate of 100 μl/well for plating, and adding 5% (v/v) CO at 37deg.C after plating 2 During the culture, observing cells every other day, and changing the liquid by half;
(4) When new cell clones appear in the 96-well plate, collecting cell culture supernatant of the well from which the clones grow, referring to step 3, performing ELISA detection by using a core antibody quantitative qualitative kit;
(5) After selection of cells from the still positive clone wells (i.e.the hybridoma cells selected) transferred to 48 wells, 1 XHT was used to culture cells at 37℃on the basis of 5% (v/v) CO 2 Is cultured in an incubator;
(6) And (3) continuing to enlarge and culture positive cloned hole cells to 24-hole plates, 12-hole plates, 6-hole plates, 25-T culture flasks and 75-T culture flasks, and simultaneously freezing and storing the screened hybridoma cells for later use.
In this step, 3 hybridoma cells producing murine anti-HBcAg monoclonal antibodies were screened out, the 3 hybridoma cells producing murine anti-HBcAg monoclonal antibodies were designated as 1B8, 7C3, 2H4 and 6F8, respectively, and the anti-HBcAg monoclonal antibodies produced by 1B8, 7C3, 2H4 and 6F8 were sent to the Kirschner company for subtype identification and light chain identification, and the identification results are shown in Table 1.
Table 1 subtype identification results of monoclonal antibodies produced by 1B8, 7C3, 2H4 and 6F8
| Hybridoma cell strain | Antibody subtypes | Antibody light chain |
| 1B8 | IgG1 | κ |
| 7C3 | IgG2b | λ |
| 2H4 | IgG1 | κ |
| 6F8 | IgG1 | κ |
5. Large-scale preparation and purification of anti-HBcAg monoclonal antibody
(1) Collecting the hybridoma cells obtained by expansion culture in a 50mL centrifuge tube, counting under a microscope, centrifuging for 10min at 800g after counting is completed, and discarding the supernatant;
(2) Cells were resuspended to 4X 10 by adding PBS buffer to a 50mL centrifuge tube 6 Obtaining a cell heavy suspension by using the total concentration of the cell heavy suspension per mL;
(3) The cell resuspension is subjected to intraperitoneal injection on Balb/c mice, and the injection dosage is 500 mu L/mouse;
(4) After 12d injection, aseptically collecting ascites in the abdominal cavity of the mouse, centrifuging at 4 ℃ for 10min in a 15mL centrifuge tube with 500 g;
(5) Collecting ascites supernatant in 1.5mL EP tube, 1 mL/tube, writing a label, and storing at-20deg.C to obtain ascites specimen;
(6) Preparing acetate buffer solution: after 59mL of solution A and 41mL of solution B were mixed, the pH was adjusted to 4.80 using hydrochloric acid (solution A: 0.06M aqueous sodium acetate; solution B: 0.06M aqueous glacial acetic acid);
(7) Taking out the ascites specimen 30min in advance, re-warming to room temperature (25 ℃) and centrifuging at 4 ℃ and 12000rpm for 10min, and taking the supernatant;
(8) The supernatant was mixed with acetate buffer according to the supernatant: acetate buffer = 1:2, dropwise adding n-octanoic acid to the mixture containing 33 mu L of n-octanoic acid in each mL of supernatant under stirring at room temperature (25 ℃), and obtaining a mixed solution;
(9) Standing the mixed solution at 4deg.C for more than 2 hr to allow it to fully precipitate, centrifuging at 12000rpm at 4deg.C for 30min, and collecting supernatant;
(10) Adding ammonium sulfate to the supernatant in 30min under ice bath until the content of ammonium sulfate in the supernatant is 0.277 g/mL to reach 45% saturation, to obtain saturated solution;
(11) Standing the saturated solution at 4deg.C for more than 2 hr to allow it to fully precipitate, centrifuging at 12000rpm at 4deg.C for 30min, and collecting protein precipitate;
(12) Dissolving protein precipitate with 1.5mL PBS buffer to obtain monoclonal antibody solution;
(13) 2. Mu.L of the monoclonal antibody solution was used to measure the protein concentration using Nanodrop 2000A280, and the protein concentration was labeled and frozen at-80 ℃.
The protein concentration of the monoclonal antibody solution obtained by culturing 1B8 in this step is 4.417mg/mL, the protein concentration of the monoclonal antibody solution obtained by culturing 7C3 is 1.737mg/mL, the protein concentration of the monoclonal antibody solution obtained by culturing 2H4 is 3.700mg/mL, and the protein concentration of the monoclonal antibody solution obtained by culturing 6F8 is 3.333mg/mL.
Experimental example 2: effect of anti-HBcAg monoclonal antibodies on expression of HBsAg, HBeAg and HBV DNA in HepG2.2.15 cells
The experimental procedure was as follows:
(1) HepG2.2.15 cells (purchased from ATCC) were used at 0.05X10 per well 6 Seed amount of each was inoculated into a 96-well plate with 200. Mu.L of DMEM medium containing 10% (v/v) fetal bovine serum per well at 37℃in 5% (v/v) CO 2 Culturing for 16h to enable cells to grow on the wall;
(2) After 16h of incubation, fresh medium was changed, and monoclonal antibody 1E10 (obtained by substituting HBcAg protein antigen with HbA2 protein antigen based on monoclonal antibody lysate prepared in Experimental example 1, hbA2 protein antigen amino acid sequence shown in SEQ ID NO. 38) was used as control protein, and monoclonal antibody lysate prepared in experimental example 1 was added to 96-well plates to protein concentrations of 50. Mu.g/mL, 100. Mu.g/mL, 200. Mu.g/mL, CO at 37℃and 5% (v/v) respectively in each well 2 Is cultured for 3d in an incubator;
(4) After 3d of culture, the cell culture supernatants from each well were collected, and the levels of HBsAg and HBeAg were detected using a quantitative assay kit for hepatitis B virus surface antigen (from Beijing Wantai) and a quantitative assay kit for hepatitis B virus e antigen (from Beijing Wantai), respectively, and HBV DNA levels were detected using a quantitative assay kit for hepatitis B virus nucleic acid (from Santa Hunan, see tables 2 to 4 for detection results.
The results in Table 2 show that the monoclonal antibodies produced by 1B8, 7C3, 2H4 and 6F8 all have a significant inhibitory effect on HBsAg in HepG2.2.15 cells, and that the more significant the effect of inhibiting secretion of HBsAg in cells is with increasing antibody concentration, wherein the effect of 1B8, 7C3 is most pronounced at 200. Mu.g/mL (P < 0.001).
The results in Table 3 show that the monoclonal antibodies produced by 1B8, 7C3, 2H4 and 6F8 also have a significant inhibitory effect on HBeAg secretion by HepG2.2.15 cells, and that the greater the inhibitory effect, the more pronounced the 1B8, 7C3 effect at 200. Mu.g/mL (P < 0.001).
The results in Table 4 show that the monoclonal antibodies produced by 1B8, 7C3, 2H4 and 6F8 also have inhibitory effect on HBV DNA expression levels in HepG2.2.15 cells, and concentration effects exist, with the effect of 1B8, 7C3 being most pronounced at 200. Mu.g/mL (P < 0.001).
TABLE 2 influence of monoclonal antibodies produced by 1B8, 7C3, 2H4 and 6F8 on the expression level of HBsAg in HepG2.2.15 cells
TABLE 3 influence of monoclonal antibodies produced by 1B8, 7C3, 2H4 and 6F8 on the expression level of HBeAg in HepG2.2.15 cells
TABLE 4 influence of monoclonal antibodies produced by 1B8, 7C3, 2H4 and 6F8 on HBV DNA expression in HepG2.2.15 cells
Experimental example 3: effect of anti-HBcAg monoclonal antibodies on expression of HBsAg, HBeAg and HBV DNA in HepAD38 cells
The experimental procedure was as follows:
referring to the method of experimental example 2, the effect of monoclonal antibodies produced by 1B8, 7C3, 2H4 and 6F8 on expression of HBsAg, HBeAg and HBV DNA in HepAD38 cells (purchased from ATCC) was examined, and the results of the examination are shown in tables 5 to 7. Monoclonal antibodies produced by 1B8 and 7C3 are sent to the Kirschner company for gene sequencing, and the sequencing results are shown in tables 8-9.
The results in Table 5 show that the monoclonal antibodies produced by 1B8, 7C3, 2H4 and 6F8 all have a significant inhibitory effect on HBsAg of HepAD38 cells, and that the more significant the effect of inhibiting secretion of HBsAg by cells is with increasing antibody concentration, wherein the effect of 1B8, 7C3 is most pronounced at 200. Mu.g/mL (P < 0.001).
The results in Table 6 show that monoclonal antibodies produced by 1B8, 7C3, 2H4 and 6F8 also have a significant inhibitory effect on HBeAg secretion by HepAD38 cells, and that the greater the inhibitory effect, the more pronounced the 1B8, 7C3 effect at 200. Mu.g/mL (P < 0.001).
The results in Table 7 show that the monoclonal antibodies produced by 1B8, 7C3, 2H4 and 6F8 also have inhibitory effects on HBV DNA expression levels in HepAD38 cells, and that concentration effects are present, with the effects of 1B8, 7C3 being most pronounced at 200. Mu.g/mL (P < 0.001).
TABLE 5 influence of monoclonal antibodies produced by 1B8, 7C3, 2H4 and 6F8 on the expression level of HBsAg in HepAD38 cells
TABLE 6 influence of monoclonal antibodies produced by 1B8, 7C3, 2H4 and 6F8 on the expression level of HBeAg in HepAD38 cells
TABLE 7 influence of monoclonal antibodies produced by 1B8, 7C3, 2H4 and 6F8 on HBV DNA expression in HepAD38 cells
TABLE 8 heavy and light chains of monoclonal antibodies produced by 1B8
TABLE 9 heavy and light chains of monoclonal antibodies produced by 7C3
It is apparent that the above examples are given by way of illustration only and are not limiting of the embodiments. Other variations or modifications of the above teachings will be apparent to those of ordinary skill in the art. It is not necessary here nor is it exhaustive of all embodiments. While still being apparent from variations or modifications that may be made by those skilled in the art are within the scope of the invention.
Claims (10)
1. An anti-HBcAg monoclonal antibody, characterized in that the heavy chain variable region of said monoclonal antibody comprises CDR1 of amino acid sequence SEQ ID No.1 or SEQ ID No.19, CDR2 of amino acid sequence SEQ ID No.2 or SEQ ID No.20, and/or CDR3 of amino acid sequence SEQ ID No.3 or SEQ ID No.21, the light chain variable region comprises CDR1 of amino acid sequence SEQ ID No.4 or SEQ ID No.22, CDR2 of amino acid sequence SEQ ID No.5 or SEQ ID No.23, and/or CDR3 of amino acid sequence SEQ ID No.6 or SEQ ID No. 24.
2. The monoclonal antibody of claim 1, wherein the heavy chain variable region of the monoclonal antibody comprises CDR1 of amino acid sequence shown as SEQ ID No.1, CDR2 of amino acid sequence shown as SEQ ID No.2 and/or CDR3 of amino acid sequence shown as SEQ ID No.3, and the light chain variable region comprises CDR1 of amino acid sequence shown as SEQ ID No.4, CDR2 of amino acid sequence shown as SEQ ID No.5 and/or CDR3 of amino acid sequence shown as SEQ ID No. 6;
alternatively, the heavy chain variable region of the monoclonal antibody comprises a CDR1 with an amino acid sequence shown as SEQ ID NO.19, a CDR2 with an amino acid sequence shown as SEQ ID NO.20 and/or a CDR3 with an amino acid sequence shown as SEQ ID NO.21, and the light chain variable region comprises a CDR1 with an amino acid sequence shown as SEQ ID NO.22, a CDR2 with an amino acid sequence shown as SEQ ID NO.23 and/or a CDR3 with an amino acid sequence shown as SEQ ID NO. 24.
3. The monoclonal antibody according to claim 1 or 2, wherein the heavy chain variable region of the monoclonal antibody comprises FR1 having the amino acid sequence shown as SEQ ID No.7 or SEQ ID No.25, FR2 having the amino acid sequence shown as SEQ ID No.8 or SEQ ID No.26, FR3 having the amino acid sequence shown as SEQ ID No.9 or SEQ ID No.27, and/or FR4 having the amino acid sequence shown as SEQ ID No.10 or SEQ ID No.28, the light chain variable region comprises FR1 having the amino acid sequence shown as SEQ ID No.11 or SEQ ID No.29, FR2 having the amino acid sequence shown as SEQ ID No.12 or SEQ ID No.30, FR3 having the amino acid sequence shown as SEQ ID No.13 or SEQ ID No.31, and/or FR4 having the amino acid sequence shown as SEQ ID No.14 or SEQ ID No. 32.
4. A monoclonal antibody according to any one of claims 1 to 3, wherein the heavy chain variable region of the monoclonal antibody comprises FR1 having the amino acid sequence shown in SEQ ID No.7, FR2 having the amino acid sequence shown in SEQ ID No.8, FR3 having the amino acid sequence shown in SEQ ID No.9 and/or FR4 having the amino acid sequence shown in SEQ ID No.10, and the light chain variable region comprises FR1 having the amino acid sequence shown in SEQ ID No.11, FR2 having the amino acid sequence shown in SEQ ID No.12, FR3 having the amino acid sequence shown in SEQ ID No.13 and/or FR4 having the amino acid sequence shown in SEQ ID No. 14.
Alternatively, the heavy chain variable region of the monoclonal antibody comprises FR1 with an amino acid sequence shown as SEQ ID NO.25, FR2 with an amino acid sequence shown as SEQ ID NO.26, FR3 with an amino acid sequence shown as SEQ ID NO.27 and/or FR4 with an amino acid sequence shown as SEQ ID NO.28, and the light chain variable region comprises FR1 with an amino acid sequence shown as SEQ ID NO.29, FR2 with an amino acid sequence shown as SEQ ID NO.30, FR3 with an amino acid sequence shown as SEQ ID NO.31 and/or FR4 with an amino acid sequence shown as SEQ ID NO. 32.
5. A gene encoding the monoclonal antibody of any one of claims 1 to 4.
6. A recombinant plasmid carrying the gene according to claim 5.
7. A host cell transfected with the recombinant plasmid of claim 6; alternatively, the genome of the host cell has integrated therein the gene of claim 5.
8. A method of producing the monoclonal antibody of any one of claims 1 to 4, comprising: inoculating the host cell of claim 7 into a cell culture medium for culturing to obtain a culture solution; the monoclonal antibody is separated and extracted from the culture solution.
9. A medicament comprising the monoclonal antibody of any one of claims 1-4, and having at least one of the following uses:
(a) Inhibiting hepatitis b virus replication;
(b) Preventing and/or treating hepatitis B virus infection; and/or the number of the groups of groups,
(c) Preventing and/or treating diseases caused by hepatitis B virus infection.
10. Use of the monoclonal antibody of any one of claims 1 to 4 or the gene of claim 5 or the recombinant plasmid of claim 6 or the host cell of claim 7 or the method of claim 8 in the preparation of a medicament having at least one of the following uses:
(a) Inhibiting hepatitis b virus replication;
(b) Preventing and/or treating hepatitis B virus infection; and/or the number of the groups of groups,
(c) Preventing and/or treating diseases caused by hepatitis B virus infection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310965283.2A CN116804053B (en) | 2023-08-02 | 2023-08-02 | anti-HBcAg monoclonal antibody and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310965283.2A CN116804053B (en) | 2023-08-02 | 2023-08-02 | anti-HBcAg monoclonal antibody and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116804053A true CN116804053A (en) | 2023-09-26 |
| CN116804053B CN116804053B (en) | 2024-01-26 |
Family
ID=88079597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310965283.2A Active CN116804053B (en) | 2023-08-02 | 2023-08-02 | anti-HBcAg monoclonal antibody and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116804053B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014193122A1 (en) * | 2013-05-31 | 2014-12-04 | (주)셀트리온 | Binding molecule able to neutralise hepatitis b virus |
| WO2017018739A1 (en) * | 2015-07-24 | 2017-02-02 | Mogam Institute For Biomedical Research | Pharmaceutical composition for preventing cccdna formation of hepatitis b virus |
| CN111620944A (en) * | 2020-06-01 | 2020-09-04 | 长春师范大学 | Fully humanized anti-hepatitis B virus monoclonal antibody, preparation method and application thereof |
| CN113138276A (en) * | 2020-01-19 | 2021-07-20 | 厦门万泰凯瑞生物技术有限公司 | Method for detecting HBcAg and antibody |
| CN113717283A (en) * | 2020-05-25 | 2021-11-30 | 厦门万泰凯瑞生物技术有限公司 | Monoclonal antibody of anti-hepatitis B virus e antigen and application thereof |
| CN116693666A (en) * | 2023-08-02 | 2023-09-05 | 南方医科大学南方医院 | Monoclonal antibody of anti-hepatitis B core antigen and application thereof |
| CN117003856A (en) * | 2023-09-27 | 2023-11-07 | 南方医科大学南方医院 | T cell receptor engineering T cell of targeting hepatitis B surface antigen |
-
2023
- 2023-08-02 CN CN202310965283.2A patent/CN116804053B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014193122A1 (en) * | 2013-05-31 | 2014-12-04 | (주)셀트리온 | Binding molecule able to neutralise hepatitis b virus |
| WO2017018739A1 (en) * | 2015-07-24 | 2017-02-02 | Mogam Institute For Biomedical Research | Pharmaceutical composition for preventing cccdna formation of hepatitis b virus |
| CN113138276A (en) * | 2020-01-19 | 2021-07-20 | 厦门万泰凯瑞生物技术有限公司 | Method for detecting HBcAg and antibody |
| CN113717283A (en) * | 2020-05-25 | 2021-11-30 | 厦门万泰凯瑞生物技术有限公司 | Monoclonal antibody of anti-hepatitis B virus e antigen and application thereof |
| CN111620944A (en) * | 2020-06-01 | 2020-09-04 | 长春师范大学 | Fully humanized anti-hepatitis B virus monoclonal antibody, preparation method and application thereof |
| CN116693666A (en) * | 2023-08-02 | 2023-09-05 | 南方医科大学南方医院 | Monoclonal antibody of anti-hepatitis B core antigen and application thereof |
| CN117003856A (en) * | 2023-09-27 | 2023-11-07 | 南方医科大学南方医院 | T cell receptor engineering T cell of targeting hepatitis B surface antigen |
Non-Patent Citations (2)
| Title |
|---|
| TATSUJI KIMURA等: "New Enzyme Immunoassay for Detection of Hepatitis B Virus Core Antigen (HBcAg) and Relation between Levels of HBcAg and HBV DNA", 《JOURNAL OF CLINICAL MICROBIOLOGY》, vol. 41, no. 5, pages 1901 - 1906 * |
| 王雪梅等: "抗HBsAg单克隆抗体的制备与生物学特性的鉴定", 《重庆医科大学学报》, vol. 33, no. 03, pages 267 - 269 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116804053B (en) | 2024-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116693666B (en) | Monoclonal antibody of anti-hepatitis B core antigen and application thereof | |
| CN105669838B (en) | Neutralizing epitopes from varicella-zoster virus gE protein and antibodies thereto | |
| US8795678B2 (en) | TLR-2 agonists and methods of use thereof | |
| CN113717283B (en) | Monoclonal antibody for resisting hepatitis B virus e antigen and application thereof | |
| JPH06500698A (en) | Nucleotides and peptides of hepatitis C virus isolates, diagnostic and therapeutic uses | |
| CN110551212A (en) | Preparation method and application of anti-GII.4 norovirus capsid protein VP1 and VLP (virus-like particle) monoclonal antibody | |
| CN102617731A (en) | Porcine circovirus-resistant type 2 egg yolk antibody and preparation method and application thereof | |
| CN113185608B (en) | High-affinity rabies virus-resistant fully-humanized monoclonal antibody and application thereof | |
| CN106366187A (en) | Monoclonal antibody for II type carp herpes virus ORF72 albumen and application thereof | |
| CN102747044B (en) | Hybridoma cell line of a kind of resisting pstudorabies virus and preparation method thereof and a kind of monoclonal antibody and application thereof | |
| CN105085626B (en) | The wide spectrum of human enterovirus is affine epitope polypeptide, antibody and application thereof | |
| CN106397581A (en) | Monoclonal antibody and preparation method thereof | |
| CN111620944A (en) | Fully humanized anti-hepatitis B virus monoclonal antibody, preparation method and application thereof | |
| CN113024666B (en) | Monoclonal antibody capable of identifying influenza A virus NP protein in broad spectrum manner and application thereof | |
| CN116804053B (en) | anti-HBcAg monoclonal antibody and application thereof | |
| CN117050183B (en) | Blocking antibody of PTN-PTPRZ1 pathway and application of blocking antibody in glioma targeted therapy | |
| CN106632676B (en) | Mouse-anti-pig PD-L1 monoclonal antibody and application thereof | |
| CN102241768B (en) | Antibody against hemagglutinin of influenza A H1N1 virus | |
| CN115141273B (en) | Monoclonal antibody of feline calicivirus and application thereof | |
| WO2018024153A1 (en) | Preparation method and use of recombinant swine fever e2 protein and subunit vaccine thereof | |
| CN108752423B (en) | TSP7 polypeptide sequence for detecting cryptosporidium parvum and application thereof | |
| CN112661852A (en) | Bispecific antibody aiming at hepatitis B virus and application thereof | |
| CN111440241A (en) | Cancer kit comprising monoclonal antibody specifically binding to ROS1 | |
| CN116589571A (en) | Encephalitis B virus antibody and application thereof | |
| CN116444663A (en) | Encephalitis B virus antibody and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |